Sectors
RDHL
RedHill Biopharma Ltd.
0.55
1 x 0.39
2 x 0.73
bid
ask
-
0.02
3.24%
2 @ 07:30 PM
0.55 -0.00 (0.20%)
| Ytd | -46.61% | |
| 1y | -67.46% |
0.54
day range
0.57
0.54
52 week range
2.79
| Open | 0.57 | Prev Close | 0.57 | Low | 0.54 | High | 0.57 | Mkt Cap | 3.34M |
| Vol | 77.61K | Avg Vol | 1.82M | EPS | N/A | P/E | N/A | Forward P/E | 210.67 |
| Beta | 3.67 | Short Ratio | 0.37 | Inst. Own | 5.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-10 | 50-d Avg | 0.66 | 200-d Avg | 0.92 | 1yr Est | 19000.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-10-03 | 2024-06 | 0 | N/A | N/A | N/A |
| 2024-07-01 | 2024-03 | 0 | N/A | N/A | N/A |
| 2024-04-26 | 2023-12 | 0 | N/A | N/A | N/A |
| 2024-01-02 | 2023-09 | 0 | N/A | N/A | N/A |
| 2023-06-12 | 2023-03 | 0 | 146.75 | N/A | N/A |
| 2023-04-06 | 2022-12 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Federation Des Caisses Desjardins Du Quebec | 3.99K | 25.23K | 0.31% |
| 2024-09-29 | Rhumbline Advisers | 979.00 | 6.19K | 0.08% |
| 2024-09-29 | Osaic Holdings Inc | 396.00 | 2.50K | 0.03% |
| 2024-09-29 | Morgan Stanley | 180.00 | 1.14K | 0.01% |
| 2024-09-29 | Capital Performance Advisors LLP | 5.00 | 31.00 | 0.00% |
| 2024-09-29 | Group One Trading, L.P. | 22.00 | 139.00 | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Fidelity NASDAQ Composite Index Fund | 41.00 | 259.00 | 0.00% |
Split
| Split | Date |
|---|---|
| 1 : 25 | 2024-08-20 |
| 1 : 40 | 2023-03-23 |